Advice
Following a full submission
Fondaparinux (Arixtra) is not recommended for use within NHS Scotland for the prevention of venous thromboembolic events (VTE) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as those undergoing abdominal cancer surgery.
Fondaparinux showed non-inferiority to one other low molecular weight heparin in preventing VTE in patients undergoing abdominal surgery. The economic case has not been demonstrated.
The licence holder has indicated their decision to resubmit.
Download detailed advice46KB (PDF)
Medicine details
- Medicine name:
- fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra)
- SMC ID:
- 287/06
- Indication:
- Prevention of venous thromboembolic events
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 August 2006